Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response
Shranjeno v:
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ferrata Storti Foundation
2015-08-01
|
| Serija: | Haematologica |
| Online dostop: | https://haematologica.org/article/view/7473 |
| Oznake: |
Brez oznak, prvi označite!
|